Co-occurrence of parkinson disease and multiple sclerosis - a critical note

Kurt A Jellinger1

  • 1Institute of Clinical Neurobiology, Alberichgasse 5/13, Vienna, A-1150, Austria. kurt.jellinger@univie.ac.at.

Insights

The rare co-occurrence of multiple sclerosis (MS) and Parkinson disease (PD) is explored, examining potential causal links and shared genetic factors. Further research is needed to understand the complex relationship between these two neurological disorders.

Area of Science:

  • Neurology
  • Neuroimmunology
  • Genetics

Background:

  • Multiple sclerosis (MS) commonly presents with movement disorders like tremor and ataxia.
  • The co-occurrence of MS with parkinsonism, and specifically Parkinson disease (PD), is exceptionally rare.
  • Existing theories on MS and PD co-occurrence range from coincidence to causality, lacking systematic evaluation.

Purpose of the Study:

  • To investigate the prevalence, characteristics, and causal relationships between MS and PD.
  • To explore potential shared genetic and pathogenic mechanisms underlying the co-occurrence of MS and PD.
  • To critically assess the evidence for a causal link between demyelinating lesions and parkinsonism.

Main Methods:

  • Systematic review of reported cases of MS and PD co-occurrence.
  • Analysis of genetic studies investigating shared genes (e.g., LRRK2, PINK1, BACE2, CD69) in MS and PD.
  • Examination of pathological findings, including iron accumulation in the substantia nigra.

Main Results:

  • While demyelinating lesions can cause parkinsonism in MS, some cases involve PD and MS as distinct coexisting diseases.
  • The presence of MS in LRRK2-associated PD suggests a role for immune function in both conditions.
  • Shared genetic factors and iron accumulation in the substantia nigra are potential common pathways.

Conclusions:

  • The co-occurrence of MS and PD, though rare, warrants critical consideration due to potential shared etiological factors.
  • Immune dysregulation and specific genetic predispositions may contribute to both MS and PD.
  • Further research is essential to elucidate the complex interplay and causal relationships between these neurological diseases.

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
334
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
158
Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.0K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
336